Congress' "blue coup" is sure to turn this 17-cent small cap into... 
As political barriers to stem cell-based medicine
come crashing down, profits of 3,000-5,000% are
all but certain for investors who ACT FAST on this
little-known, yet pioneering biotech firm that's
certain to take the lead...
Dear Friend, Election Day, Nov. 7, 2006: A bellwether date in the history of politics... And PROFIT. Here's what I mean... The Democrats' conquest of Congress - love it or loathe it - has nevertheless opened the floodgates on the medical technology millions of Parkinson's, MS, paralysis and other patients (not to mention Big Pharma) have awaited: stem cell medicine. As everyone knows, the Republican-controlled Congress (and White House) have stalled or stymied development in the stem cell research arena for years. Never before in American history has so much profitable, cutting-edge technology and innovation been held back for so long by purely ideological reasons. I'm not making any judgments about whether this was right or wrong. I'm only concerned with the dollars at stake here - your ability to make 20, 30, even 50 times your money or more in mere months as these barriers come tumbling down... Believe me, gains like these are not only possible with the little-known stock you're about to discover - they're all but inevitable now that the pendulum of power has swung the other way on The Hill. As you'll see in a moment, one "mighty mouse" of a biotech firm has an ironclad competitive advantage over other likely players in the industry... An advantage YOU can cash in on - to the tune of 3,000-5,000% or more, easily. Bottom line: Many millions of lives will soon be saved or salvaged by stem cell-based medicine - and many billions of dollars will rapidly be made by a savvy few investors (you could be one of them) in this exploding medical industry.... The question is: How big a piece of these billions of You know that old saying: "A rising tide lifts all boats." It refers to the tendency of an economic boom in a specific market segment to boost the bottom lines of ALL companies in that segment - regardless of whether they're quality investments or not. The upside of this is that everyone who gets in makes some money, at least for a little while. The downside is that once the fever of investing in "the new thing" wears off, the brutal realities of capitalism take over... Meaning only those companies with good fundamentals, sound management and a real competitive or innovative advantage survive to thrive - and the others all flame out, like the "dot bombs" so many lost out on during the early 2000s. As with the dot-com stocks, this same frenzy of investment will surely happen in the stem cell segment, starting almost immediately - and predictably, most investors will ultimately lose big. But those who get in on the few Googles, Amazons and Yahoo!s of this new multibillion-dollar marketplace will find themselves sitting on 30-50 times their money, easily... And they'll begin to do it in just a few months - a year or two at most. Now here's the payoff for YOU: In just a minute, you're going to discover the future "Google" of the stem cell universe - an all-but-unknown small cap with the patents, proprietary technology, leadership and marketing to take control of this entire market segment... And despite a relatively large market capitalization (for its stock price) of around $450 million - which it has built in the most hostile political climate imaginable, remember - it's trading for around only 17 cents RIGHT NOW. But it won't be this cheap for long now that the Once this market begins to heat up (it'll start happening very soon), thousands of savvy insiders will no doubt jump into this stock with both feet - and your window of opportunity to practically steal shares of it will be gone forever... Along with your one chance to rake in gains of 3,000-5,000% or more in less time than any other tech play I've ever seen. These are the kinds of short-term profits that would raise a seasoned venture capitalist's eyebrows! But I'm getting a little ahead of myself here, and maybe a bit ahead of you... Right now, you're probably asking yourself two questions: Who is this guy? And how does he know which stem cell stock is going to yield "Google-sized" gains over the next few years? Fair enough. First things first. My name is Addison Wiggin. I've made my living as a commentator and financial historian in the major media on matters financial (and political) for more than 12 years. I'm a regularly invited guest speaker at investment conferences and conventions the world over. You may recognize my name from my regular appearances on CNN, CNBC, FOX News and others... Or from the three New York Times best-selling money titles I've written or co-authored: Financial Reckoning Day, The Demise of the Dollar and Empire of Debt. Beyond this, I'm the publisher of several financial newsletters and investment advisories, and co-author of the long-running money and markets e-letter The Daily Reckoning (circulation 400,000)... I tell you all of this not to beat my chest, but so that you'll believe me when I say: Never before in American stock market history have both a mammoth, life-changing (and fortune-making) emerging technology AND a seismic political shift converged to offer savvy investors so great a chance at rapid, extreme profit - with relatively little risk... Now, to answer that second question. I'll do it with a confession: I really DON'T KNOW firsthand exactly why the 17-cents-per-share biotech pioneer you're about to get rich on is poised to dominate the stem cell-based medicine industry. That's because I didn't graduate from MIT with a degree in microbiology - or whatever these guys who are on the forefront of stem cell research get their degrees in... Of course, I know why this grossly undervalued firm is a sound one - I know about its strong fundamentals, inspired management and generally what its competitive advantage is. But if you're asking me to explain precisely how its "immortal" liver-based stem cell line is superior to its competitors' cells harvested from human embryos, I'm at a loss. But what I DO know is this: The most brilliant technology analyst I've ever met According to him, this'll happen once the sure-to-overheat stem cell market corrects - and the companies that have truly innovative, patented or proprietary biotechnology are the only ones left standing... That's when you'll be sitting pretty - if you got in on this future industry leader at 17 CENTS A SHARE! This genius/scientist/consultant/Renaissance man's name is Jonathan Kolber. And fortunately for you, he now writes one of the newsletters I publish, The Emerging Capital Report - which means he could soon be advising you about not only the life-changing developments, but also the hush-hush dealings of the emerging tech world that could render you richer than rich... Like the future "Google" of the stem cell game I've been telling you about. Keep reading, and in just a minute, I'll show you how to get a FREE Special Report on this incredible small-cap biotechnology profit play I asked Jonathan to write specifically for readers like you... CAUTION: Uncharted investing waters ahead - but In the relatively uncharted waters of stem cell profiteering, it's especially critical that you NOT put money into firms without the factors I mentioned above: strong fiscal fundamentals, competent management and a distinct competitive advantage. And according to Jonathan Kolber, one of the best and brightest tech analysts on Earth, it can be very challenging to separate the wheat from the chaff among the firms that'll soon be vying for supremacy in the stem cell markets... That's because biotech and stem cell-based medicine are endlessly complex. Things like proprietary technology, patent infringement, intellectual property and the legality of benefit claims are difficult to fully understand for even the most seasoned tech investor - and nearly impossible for the average investor. Without expert analysis, you'd have to be part scientist (or at least a genius) to grasp the ins and outs and to make the right calls with your money... Kind of like Jonathan Kolber is, in other words. That's why I asked him to write a Special Report on this once-in-a-lifetime biotech profit play. It's called "Google" Made Flesh: 30-50 Times Your Money on Tomorrow's Stem Cell Front-Runner. In it, you'll learn all the details about this company: This in-depth Special Report is yours FREE below. Keep reading. But right now, I want to tell you why... Few companies are even able to be stem cell In case you're not entirely up to speed on stem cells, here's what the big deal is... Without getting too technical, stem cells are "mother" cells that can change (or be changed by a small number of scientists - like those you're about to meet) into many types of bodily tissue and blood cells. Since I'm not a scientist myself, I'll let this definition from IFOPA.org explain it better: "Stem cells are of embryonic origin and possess the properties of both self-renewal and differentiation into a wide variety of tissue types." Basically, stem cells are the key to fighting all kinds of degenerative diseases like MS, motor function and movement disorders like Parkinson's disease and others - even spinal cord injuries like what rendered the late Christopher Reeve wheelchair-bound... In other words, they're a quantum leap across a broad spectrum of medicine. They're also the key to a quantum leap in your portfolio if you get in now... Since stem cell-based medicine is relatively uncharted territory, I want to show you a bit about how vast the market for this technology is. Consider: DRUG DEVELOPMENT: $8.5 BILLION PER YEAR Big Pharma spends around $8.5 billion developing 400 or more drugs every year. Testing these drugs on various organ tissues represents a large percentage of this cost - and the results aren't always perfect. Remember the VIOXX debacle? That happened because the manufacturer was looking for liver toxicity, like what other painkillers can cause. What it didn't count on (or test adequately for) was heart toxicity, and it cost the company untold billions in liability awards and in its stock price. It also cost thousands of Americans their lives... Now, imagine what Big Pharma would pay to the only company out there that can offer it a way to test drugs across all eight organ tissue groups. Imagine what such a company could charge for that service - saving a drug maker from just one "VIOXX." The biotech firm Jonathan's recommending in his Special Report is the only firm out there able to offer such comprehensive organ group testing through the magic of its proprietary stem cell technology. At the bargain-basement rate of $5 million per drug (less than even a small court liability award), this company could rake in $2 billion per year from just this one facet of its business. What do you think THAT would do to its 17-cent stock price? In the 23 years since he graduated with an MBA from the prestigious Carlson School of Management at the University of Minnesota, Jonathan Kolber has done just about everything in the technology world. He has co-founded, managed and VPed several successful technology companies between the early '80s and the late '90s. He has served as a consultant and editor on countless winning business plans for tech ventures. He has served three separate terms as president of a consulting firm specializing in emerging technology investment. He has guided his and other companies to multiple patents. And he has solicited and directed tens of millions of dollars in venture capital for his own enterprises and others'. Along the way, he has accrued vast knowledge and experience in fields such as supercomputers and software, nuclear fusion and alternative energy, advanced nutrition and pharmaceuticals, e-commerce and the Internet, robotics, genetics, AI and nanotechnology. Now he puts all of this expertise to work for one purpose: informing and enriching the readers of his newsletter, The Emerging Capital Report. LIVER ASSISTANCE: $2.5 BILLION PER YEAR Around 10,000 liver transplants happen in the U.S. and Europe each year - at an average cost of around $250,000. Another 20,000 or so are on waiting lists. Sadly, many of these people die, or slowly decay to a shadow of their former selves... Now, imagine a company that could make a liver-assistance device that utilizes real human liver cells (derived from stem cells) that can continually regenerate themselves while these patients wait for liver transplants - or even eliminate the need for a liver transplant altogether. Now imagine such a device is one-fifth the cost of the average transplant! Well, such a device is almost a foregone conclusion for this small-cap biotech wonder I've been talking about. Think insurance companies wouldn't jump at the chance to buy into this technology, instead of shelling out for all those livers - and the complications that inevitably follow liver surgery? Do you think this stock will stay 17 cents a share once word of this innovation gets out? PARKINSON'S AID: $1.2 BILLION IN THE U.S. AND EUROPE ALONE Everyone knows about Parkinson's disease - one need only look at Muhammad Ali or Michael J. Fox to see the ravages of it at work. Injections of fetal cell tissues have been shown to cure the disease, but it takes roughly 10 such fetuses to generate enough stem cells to treat just one patient. There are at least 50,000 Parkinson's patients in the U.S. and Europe right now... But what if there were a company that had a way to generate a nearly unlimited supply of uncontaminated stem cells that could successfully treat Parkinson's disease - without using ANY human fetuses? Again, the small biotech company Jonathan told me about has developed exactly this. Over 100 tests of the firm's generated brain neuron cells prove the process works at treating this dreaded disease! Now, imagine how many patients (or their insurance companies) would buy such a treatment for, say, $25 grand. Early estimates show it's possible at this price... Another $1.25 billion in revenue to push "BioGoogle's" stock price into profit-land. These are just a few of the market advantages this stock has over its competitors that you'll learn about in Jonathan's "Google" Made Flesh: 30-50 Times Your Money on Tomorrow's Stem Cell Front-Runner... There's another one that could dwarf these three (yes, it's in the report, too) - dumping as much as $10 billion into this small tech player's coffers. And that's exactly what the "in-the-know" analyst I depend on is predicting will soon happen. Want to learn a bit more about him? Keep reading... Meet the only man I trust for For more than 20 years, Jonathan Kolber has lived and breathed technology... And not just as an analyst. He's been a hands-on pioneer in various technological ventures, some of them life-changing products and services you may have even used yourself - like try-before-you-buy computer software, and those limited-use DVD movies available at places like 7-Eleven, Papa John's and other national chains, just to name a few... In August 2004, Jonathan Kolber recommended to readers of The Emerging Capital Report a 17-cent stock in a small nanotech/nuclear science company helmed by a Russian defector - a physics whiz groomed by the Kremlin since boyhood for a key role in the Cold War's nuclear standoff... The firm had developed transformational technologies that could neutralize radioactive pollutants in water supplies, detect modern terror threats like "suitcase nuke" bombs and produce pinhead-sized batteries that last for years by harnessing atomic power. Earlier this spring, that stock had grown to $1.96 per share, more than 1,100% of its original recommendation price - and with the war on terror and concerns over energy shortages at an all-time high, it's got nowhere to go but up. Those who listened to the most accomplished technology analyst in the investment world have gained more than 10 times their money... And the stock's STILL a steal. According to Jonathan, there's easily another 1,000% or more in possible profits to be made for those who buy in now. Find out all the details in your FREE Special Report entitled The Technology Stock of the Decade: 50-fold Gains as This Firm Solves Some of the World's Biggest Problems. Here's why that's important: Because he's been a winner in the tech trenches himself, Kolber has seen a lot of technologies come and go over the last two decades. More than anyone else I've ever met, this fact qualifies him to know the ones with the ability to transform our lives from the ones that are simply fads - or flops. Beyond this, Jonathan's got the connections mere journalists don't. He knows people like world-renowned inventor and futurist Ray Kurzweil, a Nobel laureate economist and a former assistant secretary of the U.S. Department of Energy. He's got contacts on both sides of the tech-investing fence - the money side and the science side - that include a veritable "who's who" of scientists in the chemistry and physics communities... And they all TALK to him. Plus, he attends just about every cutting-edge technology conference and gathering in the free world, no matter how obscure. That's how he discovers companies like the electro-tech micro-player I've been crowing about since the start of this bulletin. That's why two years ago, I hired him away from his latest technology venture to be the editor of The Emerging Capital Report investment advisory - to transition from developing new transformational technologies to alerting investors about them. Now, instead of focusing on just the one segment of the technology market he's trying to compete in (or to pioneer), Jonathan is focused on the entire spectrum of the emerging technology world. This perspective allows him to think three, four, even 10 moves ahead - like a grandmaster in the tech-investing chess game. From his new vantage point as an investment analyst, he gets to see the entire game board of tech-industry trends and opportunities that open the door for profits that are bordering on obscene - like the small U.S. biotechnology player I mentioned earlier that's about to become the "Google" of the stem cell industry... I'm talking about venture capitalist-type gains of 20, 50, even 100 times your money or more. Enough to turn just a few thousand bucks into enough money to retire with - on your own private island. The company I've been telling you about is just one of the dozens Jonathan has alerted his readers to, some of which have already gained over 1,000% in value...
dollars in certain profit do YOU want to make?
Democrats control Congress - your window of
greatest opportunity is closing fast
is utterly convinced that this stock could go up in
value 30-50 times over
your FREE map through the rocks to mega-profits
is just ahead, too...
competitors, but only one is equipped to revolutionize
the industry - and after RIGHT NOW, it may
never be dirt-cheap again
the real scoop on technologies
